Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 7/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.49 |
| ▸ | EGFR | P00533 | 8/20 | 0.49 |
| ▸ | HCK | P08631 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | BLK | P51451 | 1/20 | 0.40 |
| ▸ | BMX | P51813 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16788366 | 0.97 | BTK (0.86) | BTKERBB2EGFR | |
| SCHEMBL19986670 | 0.97 | BTK (0.86) | BTKERBB2EGFR | |
| SCHEMBL19993798 | 0.89 | BTK (1.00) | BTKERBB2EGFRITK | |
| SCHEMBL166896 | 0.89 | BTK (1.00) | BTKERBB2EGFRITK | |
| SCHEMBL19728633 | 0.88 | BTK (0.62) | BTKERBB2EGFR | |
| SCHEMBL18905245 | 0.87 | BTK (0.61) | BTKERBB2EGFR | |
| SCHEMBL122280 | 0.84 | BTK (1.00) | BTKEGFRITK | |
| SCHEMBL169757 | 0.84 | BTK (0.85) | BTKERBB2EGFRHCKSRC | |
| SCHEMBL122566 | 0.81 | BTK (0.94) | BTKEGFRITK | |
| SCHEMBL124181 | 0.80 | BTK (0.82) | BTKERBB2EGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153896-A1 | METHODS OF TREATING FIBROSIS | PHARMACYCLICS LLC | 2018-06-07 | — | — | US | disclosed |
| US-20180078558-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180071294-A1 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER | PHARMACYCLICS LLC | 2018-03-15 | — | — | US | disclosed |
| US-20180071295-A1 | BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS AND USES THEREOF | PHARMACYCLICS LLC | 2018-03-15 | — | — | US | disclosed |
| US-20180037583-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS LLC (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180028537-A1 | Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor | PHARMACYCLICS LLC | 2018-02-01 | — | — | US | disclosed |
| US-20170354655-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | PHARMACYCLICS LLC | 2017-12-14 | — | — | US | disclosed |
| US-9795604-B2 | Methods of treating and preventing graft versus host disease | PHARMACYCLICS LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-9730938-B2 | Bruton's tyrosine kinase inhibitor combinations and uses thereof | PHARMACYCLICS LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170209462-A1 | BTK INHIBITOR COMBINATIONS FOR TREATING MULTIPLE MYELOMA | PHARMACYCLICS LLC | 2017-07-27 | — | — | US | disclosed |
| US-20160038495-A1 | BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS AND USES THEREOF | PHARMACYCLICS LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160032404-A1 | BIOMARKERS FOR PREDICTING RESPONSE OF DLBCL TO TREATMENT WITH A BTK INHIBITOR | PHARMACYCLICS LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160022684-A1 | BET INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | PHARMACYCLICS LLC | 2016-01-28 | — | — | US | disclosed |
| US-20150361504-A1 | BIOMARKER FOR PREDICTING RESPONSE OF CLL TO TREATMENT WITH A BTK INHIBITOR | PHARMACYCLICS LLC | 2015-12-17 | — | — | US | disclosed |
| US-20150352116-A1 | HDAC INHIBITOR AND BTK INHIBITOR COMBINATIONS | PHARMACYCLICS LLC | 2015-12-10 | — | — | US | disclosed |
| US-20150238490-A1 | BIOMARKERS FOR PREDICTING RESPONSE OF DLBCL TO TREATMENT WITH IBRUTINIB | PHARMACYCLICS LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150118222-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | PHARMACYCLICS LLC | 2015-04-30 | — | — | US | disclosed |
| US-20150118209-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-04-30 | — | — | US | disclosed |
| US-20150044217-A1 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | disclosed |
| US-20150038518-A1 | METHODS FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037583-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | BTK 1/4885ERBB2 101/4885EGFR 1723/4885 |
| US-20180153896-A1 | METHODS OF TREATING FIBROSIS | MYLK, MMP1, MMP8 | BTK 18/4885ERBB2 1427/4885EGFR 1613/4885 |
| US-20150118222-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | BTK, LCK, LYN | BTK 1/4885ERBB2 47/4885EGFR 544/4885 |
| US-20150352116-A1 | HDAC INHIBITOR AND BTK INHIBITOR COMBINATIONS | HDAC1, HDAC2, BTK | BTK 3/4885ERBB2 823/4885EGFR 2538/4885 |
| US-20150038518-A1 | METHODS FOR THE TREATMENT OF SOLID TUMORS | HDAC1, HDAC4, HDAC2 | BTK 1268/4885ERBB2 1181/4885EGFR 1866/4885 |
| US-20180078558-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | FCGR3B, BTK, IGLV6-57 | BTK 2/4885ERBB2 1670/4885EGFR 1605/4885 |
| US-20180071294-A1 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER | ERBB2, EGFR, ERBB3 | BTK 10/4885ERBB2 1/4885EGFR 2/4885 |
| US-20150118209-A1 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | BLK, DCK, CILK1 | BTK 8/4885ERBB2 1467/4885EGFR 2307/4885 |
| US-20180071295-A1 | BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS AND USES THEREOF | BTK, LYN, PIM1 | BTK 1/4885ERBB2 104/4885EGFR 611/4885 |
| US-20170354655-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | BTK, TLR3, TLR9 | BTK 1/4885ERBB2 74/4885EGFR 366/4885 |
| US-20150044217-A1 | METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER | ERBB2, EGFR, ERBB3 | BTK 10/4885ERBB2 1/4885EGFR 2/4885 |
| US-20160022684-A1 | BET INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | BTK, MYC, BCL6B | BTK 1/4885ERBB2 112/4885EGFR 636/4885 |
| US-20170209462-A1 | BTK INHIBITOR COMBINATIONS FOR TREATING MULTIPLE MYELOMA | BTK, SYK, BCL6B | BTK 1/4885ERBB2 401/4885EGFR 871/4885 |
| US-20160038495-A1 | BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS AND USES THEREOF | BTK, LYN, PIM1 | BTK 1/4885ERBB2 104/4885EGFR 611/4885 |
| US-20180028537-A1 | Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor | BTK, LYN, SYK | BTK 1/4885ERBB2 53/4885EGFR 870/4885 |
| US-20150238490-A1 | BIOMARKERS FOR PREDICTING RESPONSE OF DLBCL TO TREATMENT WITH IBRUTINIB | BCL3, BCL6B, BCL6 | BTK 4/4885ERBB2 961/4885EGFR 1648/4885 |
| US-20150361504-A1 | BIOMARKER FOR PREDICTING RESPONSE OF CLL TO TREATMENT WITH A BTK INHIBITOR | BTK, BCL6B, LYN | BTK 1/4885ERBB2 58/4885EGFR 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.